Biotechnology Virtual Clinical Trials Law In Russia.
1. Introduction
Biotechnology Virtual Clinical Trials (VCTs) refer to clinical research conducted through digital technologies, telemedicine, wearable medical devices, artificial intelligence (AI), electronic health records, remote patient monitoring and online consultations. Unlike traditional clinical trials, which require participants to visit hospitals and research centres regularly, virtual trials allow certain research activities to take place remotely.
In Russia, virtual clinical trials are governed by a combination of pharmaceutical legislation, medical regulations, personal-data protection laws, telemedicine rules and ethical standards.
Russia does not have a completely separate statutory framework exclusively dedicated to virtual clinical trials. Instead, existing clinical-trial legislation applies to research using digital and remote technologies. The principal objective is to protect participants' safety, ensure reliable scientific evidence and prevent misuse of medical information.
2. Principal Legislative Framework
The following legislation is particularly relevant:
A. Federal Law No. 61-FZ of 12 April 2010 – On Circulation of Medicines
This is the principal legislation governing pharmaceutical clinical trials in Russia.
Articles 38–43 establish requirements concerning:
Authorisation of clinical trials.
Clinical-trial institutions.
Investigator responsibilities.
Ethical review.
Informed consent.
Patient confidentiality.
Insurance and protection of participants.
Clinical-trial contracts.
Article 38 requires clinical trials to follow Good Clinical Practice (GCP). It also requires appropriate authorisation and participation of accredited medical institutions. Consequently, a sponsor cannot avoid regulatory requirements merely because a trial uses mobile applications or remote monitoring.
WIPO+1
B. Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection
This legislation establishes general principles of medical care, patient rights, medical confidentiality and informed consent.
Article 36.2 is particularly important because it regulates medical assistance using telemedicine technologies.
Virtual clinical trials may involve remote consultations, electronic transmission of medical information and distance-based observation. However, telemedicine does not automatically authorise every research activity to be performed remotely.
C. Federal Law No. 152-FZ – On Personal Data
This legislation regulates the collection, processing, storage and disclosure of personal information.
Virtual trials frequently collect sensitive information, including:
Genetic information.
Biometric information.
Medical histories.
Wearable-device measurements.
Digital health records.
Patient identification information.
Sponsors and research organisations must establish lawful grounds for processing such information and implement appropriate security safeguards.
D. Ministry of Health Order No. 200n of 1 April 2016
This Order approves Russian Good Clinical Practice rules.
It regulates clinical-trial planning, organisation, monitoring, auditing, documentation and reporting. Its requirements are particularly relevant when clinical-trial activities are performed using remote technologies.
Consultant Plus+1
3. Legal Recognition of Virtual Clinical Trials
An important legal question is whether Russia recognises fully decentralised clinical trials.
The Russian regulatory framework recognises clinical research conducted through approved medical institutions, but it does not establish a general exemption for decentralised trials.
Certain activities can be conducted remotely, depending on the approved protocol and applicable medical requirements.
Examples include:
Remote patient consultations.
Electronic collection of health information.
Wearable-device monitoring.
Digital patient questionnaires.
Remote follow-up appointments.
Electronic communication between investigators and participants.
However, activities involving physical examinations, laboratory testing, biological sampling or emergency medical intervention may still require direct medical involvement.
The sponsor must demonstrate that remote procedures do not compromise patient safety or scientific reliability.
4. Electronic Informed Consent and Patient Rights
Informed consent is one of the most important legal requirements in virtual clinical trials.
Article 43 of Federal Law No. 61-FZ establishes the rights of clinical-trial participants.
Participants must receive information concerning:
The investigational medicinal product.
The purpose and duration of the research.
Expected benefits and possible risks.
Participation conditions.
Procedures for reporting unexpected adverse effects.
Insurance arrangements.
Confidentiality protections.
Participants also have the right to withdraw from a clinical trial at any stage.
Important 2026 development: From 1 January 2026, amendments provide for electronic informed consent in medicinal-product clinical trials. Consent may be documented electronically and signed using an enhanced qualified electronic signature or a simple electronic signature through the Unified Identification and Authentication System. Participants may request paper consent instead.
static-0.minzdrav.gov.ru+1
This development is particularly important for virtual clinical trials because it provides a statutory basis for electronic consent rather than requiring every participant to sign a paper document physically.
Nevertheless, electronic consent must remain voluntary, understandable and properly documented.
5. Remote Monitoring and Artificial Intelligence
Virtual clinical trials frequently use AI systems, wearable devices and digital monitoring platforms.
For example, a participant suffering from a cardiovascular condition may wear a connected device that records heart rate, blood pressure and other physiological indicators.
The collected information may be transmitted to investigators for assessment.
Russian law requires clinical-trial activities to comply with applicable medical and GCP standards.
Important legal responsibilities include:
Ensuring the accuracy of digital measurements.
Maintaining reliable electronic records.
Preventing unauthorised access.
Investigating adverse events.
Maintaining investigator supervision.
Ensuring appropriate medical intervention.
AI cannot independently replace the investigator's legal and professional responsibilities.
If an AI monitoring system fails to identify a serious adverse event, responsibility may arise depending on the conduct of the sponsor, investigator, medical institution and technology provider.
6. Data Protection and Cross-Border Information Transfers
International virtual clinical trials create significant data-protection challenges.
A Russian participant's medical information may be collected by a Russian hospital and transferred to a foreign sponsor, research organisation or cloud-service provider.
Federal Law No. 152-FZ becomes particularly important in these circumstances.
Relevant compliance requirements include:
Establishing a lawful basis for personal-data processing.
Obtaining appropriate consent where required.
Protecting medical confidentiality.
Implementing cybersecurity safeguards.
Complying with applicable Russian data-localisation requirements.
Following the statutory requirements for cross-border transfers.
Genetic and biometric information can create additional risks because disclosure may affect not only the participant but potentially their relatives.
Therefore, virtual clinical-trial sponsors must establish clear data-sharing agreements and appropriate access controls.
7. Important Judicial Decisions and Case Laws
Russian reported judicial decisions specifically addressing fully decentralised clinical trials remain limited. Nevertheless, important judicial decisions concerning conventional clinical research provide principles applicable to virtual trials.
Case 1: Traskunova v. Russia (2022), Application No. 21648/11, European Court of Human Rights, 30 August 2022
Important clinical-trial precedent
This is one of the most significant judgments concerning clinical-trial participant protection in Russia.
The case concerned a woman who died while participating in clinical trials of an experimental medicine intended to treat schizophrenia.
The European Court of Human Rights examined deficiencies involving medical examinations, monitoring and the protection of the participant.
The Court found a violation of Article 2 of the European Convention on Human Rights, concerning the right to life.
Legal principles:
Clinical-trial participants require effective protection.
Medical examinations must be appropriately conducted.
Investigators must monitor participants' health.
Adverse medical developments must receive proper attention.
Regulatory safeguards must be effectively implemented.
Relevance to virtual trials: Remote monitoring cannot become an excuse for inadequate medical supervision. Digital platforms must provide reliable mechanisms for identifying and responding to serious medical risks.
Bailii+1
Case 2: Hristozov and Others v. Bulgaria (2012), Applications Nos. 47039/11 and 358/12
The European Court of Human Rights considered complaints concerning access to experimental cancer treatments.
The case examined the relationship between experimental medical treatment, patient autonomy and the State's regulatory responsibilities.
Legal principle: Access to experimental treatment must be considered within the applicable regulatory framework, rather than treated as an unrestricted individual entitlement.
Relevance: Virtual clinical-trial platforms must distinguish between authorised clinical research and the provision of unapproved experimental treatments.
Bailii+1
Case 3: Traskunova v. Russia – Application of informed-consent principles
A further important aspect of the same 2022 judgment concerns the quality of informed consent.
The Court examined whether participants had received adequate information and whether the safeguards governing participation had been properly implemented.
Legal principle: Obtaining a signature alone does not establish that informed consent has been meaningfully obtained.
Relevance: Digital consent systems must ensure that participants genuinely understand the research, its risks and their right to withdraw.
These decisions should not be misrepresented as judgments directly deciding the legality of virtual clinical trials. They establish broader principles relevant to their regulation.
8. Regulatory Challenges
Russia faces several important challenges in developing virtual clinical trials:
First, technological reliability: Wearable devices and digital platforms may generate inaccurate or incomplete medical information.
Second, cybersecurity: Medical information can be exposed through hacking, unauthorised access or inadequate storage systems.
Third, participant protection: Remote participation may make it difficult to identify emergencies or deteriorating medical conditions.
Fourth, regulatory responsibility: Disputes may arise concerning responsibility between sponsors, investigators, hospitals and technology companies.
Fifth, international cooperation: Cross-border clinical research requires compliance with Russian pharmaceutical, medical and personal-data regulations.
9. Conclusion
Biotechnology Virtual Clinical Trials in Russia operate within the broader framework of Federal Laws No. 61-FZ and No. 323-FZ, personal-data legislation and Good Clinical Practice requirements.
The introduction of electronic informed consent provisions in 2026 represents an important development in digital clinical research.
The judgment in Traskunova v. Russia demonstrates that participant safety, informed consent, medical supervision and effective regulatory enforcement remain essential.
Ultimately, Russia's virtual clinical-trial framework must balance technological innovation with human dignity, medical ethics, scientific reliability and legal accountability.
The central legal principle is that digitalisation may change how clinical trials are conducted, but it cannot reduce the legal protection owed to research participants.

comments